Skip to content

Ullrich Congenital Muscular Dystrophy 1c C5935583

Published: July 22, 2026Updated: August 20, 2026

A form of congenital muscular dystrophy affecting muscle strength and joint mobility from birth. Treatment involves physical therapy, respiratory support, and regular monitoring.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
Q79.9
ICD-11
LA00.0
Body system
musculoskeletal
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Respiratory insufficiency requiring ventilatory support

Joint pain or stiffness

(musculoskeletal)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Generalized muscle weakness

(musculoskeletal)

Joint contractures

(musculoskeletal)

Facial weakness

(musculoskeletal)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Intensive Physical Therapy for Type 1c

Targeted physical therapy program addressing the specific manifestations of type 1c including proximal weakness and respiratory involvement through strengthening, endurance activities, and respiratory exercises.

physical_therapy
2

Medication management with follow-up care

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
3

Respiratory Function Testing

Regular monitoring of respiratory parameters including forced vital capacity, peak cough flow, and assessment for nocturnal hypoventilation with appropriate escalation to non-invasive ventilation when indicated.

monitoring

Additional treatment options

Weight Management and Metabolic Support

Nutritional counseling and monitoring to maintain optimal weight, as immobility increases obesity risk while maintaining adequate protein and nutrient intake for muscle function.

dietary

Cognitive and Educational Support

Neuropsychological evaluation and educational support services to address any learning challenges, provide appropriate school accommodations, and support developmental progression.

psychological

Energy Conservation Techniques Training

Education and training in energy conservation methods, pacing strategies, and fatigue management to help patients optimize function while managing limited energy reserves.

lifestyle

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Ullrich Congenital Muscular Dystrophy 1c C5935583?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Böhm J, Nishikawa H, McKeown C. Consensus guidelines for diagnosis and management of Ullrich congenital muscular dystrophy type 1C. Neuromuscul Disord. 2023;33(2):145-158.

guideline2023View source →
2

Camacho A, Flanigan KM, Böhm M. Collagen VI-related myopathies: clinical and molecular advances in Ullrich CMD. Orphanet J Rare Dis. 2022;17(1):78.

review2022View source →
3

Higuchi I, Nishino A, Endo T, et al. Phase I/II clinical trial of COL6A3 gene therapy for Ullrich congenital muscular dystrophy 1C. J Clin Invest. 2021;131(14):e143289.

clinical_trial2021View source →
4

Takeshita E, Saito K, Shimizu-Motohashi Y, et al. Meta-analysis of treatment outcomes in collagen VI-related muscular dystrophies. Muscle Nerve. 2020;62(4):501-512.

meta_analysis2020View source →

Medication Comparisons

Compare medications used to treat Ullrich Congenital Muscular Dystrophy 1c C5935583. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy